Orchid Pharma Share Price Jumps to Fresh 52-Week High at Rs 1,143: Here’s Why
- September 22, 2026
- Posted by: Harsh Piplani
- Category: News
Orchid Pharma Share Price rose to Rs 1,136.25 on 22 September 2026, up 5.07% from the previous close of Rs 1,081.45, and touched a fresh 52-week high of Rs 1,142.65 during the session. The company’s market capitalisation stood at Rs 5,923.25 crore. This Orchid Pharma Share Price move is relevant because it confirms a one-year high event on the trading screen, while the supplied data does not establish a company-specific catalyst. For readers tracking Orchid Pharma Share Price Today, the key point is the verified price event, the day’s range and the valuation backdrop around Orchid Pharma Stock News and Orchid Pharma Share News. Univest is covering the event with a factual market note anchored to the data provided.
At the open, Orchid Pharma traded at Rs 1,087.75, below the session high and above the day low of Rs 1,073.75. The move of Rs 54.80 reflects a gap between the previous close and the current session outcome, while turnover was Rs 1.72 crore. In practical terms, Orchid Pharma Share Price Today is trading above the prior close and at a fresh yearly high, which makes the session notable in the context of Orchid Pharma Stock News and Orchid Pharma Share Price Live. The data confirms the price event, but it does not identify a company-specific trigger. Univest keeps the focus on verified facts, not assumptions, so investors can read the Orchid Pharma Share Price Update alongside the financial and sector numbers that follow.
Orchid Pharma Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,136.25 |
| Previous Close | Rs 1,081.45 |
| Today's Move | +Rs 54.8 (+5.07%) |
| Open | Rs 1,087.75 |
| High | Rs 1,142.65 |
| Low | Rs 1,073.75 |
| Turnover | Rs 1.72 crore |
| Market Capitalisation | Rs 5,923.25 crore |
Orchid Pharma Ltd. (ORCHPHARMA) traded at Rs 1,136.25 versus the previous close of Rs 1,081.45, a rise of 5.07%. The stock opened at Rs 1,087.75, reached a high of Rs 1,142.65 and touched a low of Rs 1,073.75.
Orchid Pharma Share Price Today shows a strong session on a factual basis: the stock opened at Rs 1,087.75, moved between Rs 1,073.75 and Rs 1,142.65, and finished at Rs 1,136.25 after closing the prior session at Rs 1,081.45. The day change was Rs 54.80, or 5.07%, and the session high matched the fresh 52-week high of Rs 1,142.65. That means the stock set a one-year high during the day and remained near that level at the close. Turnover of Rs 1.72 crore provides a value-based trading reference, while the price action itself confirms a fresh high event for Orchid Pharma Share Price and Orchid Pharma Stock News today. For readers following Orchid Pharma NSE and Orchid Pharma BSE updates, the main takeaway is the exact price movement and the day’s extreme values, not a company-specific explanation that is not supported by the supplied data. Univest presents this as a verified market event and not a causal claim.
Orchid Pharma Ltd. (ORCHPHARMA) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 5,923.25 crore |
| P/E Ratio | 747.32x |
| P/B Ratio | 4.13x |
| ROE | 0.7% |
| ROCE | 1.11% |
| EPS | Rs 1.45 |
| Book Value Per Share | Rs 261.65 |
| Dividend Yield | 0% |
Orchid Pharma Ltd. (ORCHPHARMA) fundamental metrics show P/E 747.32x, P/B 4.13x, ROE 0.7%, ROCE 1.11%. These figures provide context only and are not a buy or sell signal.
Orchid Pharma Ltd. has a market capitalisation of Rs 5923.25 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 747.32x, P/B at 4.13x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 0.7% and ROCE of 1.11%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 1.45, book value per share of Rs 261.65, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 32.39x, median ROE of 11.78%, median ROCE of 13.65%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 747.32x |
| Benchmark Median P/E | 32.39x |
| Benchmark Average P/E | 45.36x |
| Benchmark P/E Range | 3.37x to 421.02x |
| Company P/B Ratio | 4.13x |
| Benchmark Median P/B | 2.98x |
| Company ROE | 0.7% |
| Benchmark Median ROE | 11.78% |
| Company ROCE | 1.11% |
| Benchmark Median ROCE | 13.65% |
| Company Market Capitalisation | Rs 5,923.25 crore |
| Benchmark Median Market Cap | Rs 729.99 crore |
Orchid Pharma Ltd. (ORCHPHARMA) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Orchid Pharma Ltd. (ORCHPHARMA) has a P/E ratio of 747.32x, which is above the benchmark median of 32.39x, a difference of +2,207.26%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Orchid Pharma Ltd. (ORCHPHARMA) has a ROE of 0.7%, which is below the benchmark median of 11.78%, a difference of -94.06%. Orchid Pharma Ltd. (ORCHPHARMA) has a ROCE of 1.11%, which is below the benchmark median of 13.65%, a difference of -91.87%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| IOL Chemicals And Pharmaceuticals Ltd. | IOLCP | 5,957.14 | 35.47 | 3.2 | 7.9 | 10.65 |
| FDC Ltd. | FDC | 5,746.38 | 20.18 | 2.26 | 11.81 | 15.93 |
| SENORES PHARMACEUTICALS L | SENORES | 6,474.21 | 50.69 | 6.65 | 14.14 | 15.66 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | 5,393.49 | 110.78 | 5.14 | 17.41 | 18.16 |
| Morepen Laboratories Ltd. | MOREPENLAB | 6,624.76 | 47.71 | 5.15 | 7.96 | 10.19 |
Orchid Pharma Ltd. (ORCHPHARMA) has a P/E ratio of 747.32x compared with the displayed peer median of 47.71x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 0.7% compares with a peer median of 11.81% across the companies shown in the table. ROCE stood at 1.11% versus the displayed peer median of 15.66%, providing a capital-efficiency comparison. Orchid Pharma Ltd. (ORCHPHARMA) has a market capitalisation of Rs 5,923.25 crore. Among the 5 peers shown, 3 have a larger market capitalisation.
Why Investors Are Watching Orchid Pharma
- Orchid Pharma Share Price hit a fresh 52-week high of Rs 1,142.65 and closed at Rs 1,136.25.
- The stock moved Rs 54.80 higher, or 5.07%, from the previous close of Rs 1,081.45.
- Market capitalisation stood at Rs 5,923.25 crore on the supplied data.
- EPS was Rs 1.45, book value per share was Rs 261.65 and dividend yield was 0.00.
- P/E at 747.32 and ROE at 0.70% sit far from the same-industry benchmark values.
About Orchid Pharma
Orchid Pharma Ltd. operates in Healthcare and is classified in Pharmaceuticals & Drugs. The supplied data supports a market and financial profile rather than a detailed operating description. For Orchid Pharma Share Price readers, the company context available here is built around sector classification, financial metrics and benchmark comparisons. Univest keeps the focus on verified company data, including revenue, profit, valuation and ownership-related details when supplied, so readers can place the stock event in a structured market context.
Track Orchid Pharma Share Price on Univest
Use Orchid Pharma Ltd. (ORCHPHARMA) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Track Orchid Pharma Share Price on Univest for live price updates, share price today coverage, fundamental ratios, shareholding pattern when available, market cap, 52-week levels and company news. Univest also brings together stock analysis, sector context and peer comparison in one place for readers following Orchid Pharma Share Price Today, Orchid Pharma Stock News and Orchid Pharma Latest News.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is Orchid Pharma Share Price today?
Ans. Orchid Pharma Share Price was Rs 1,136.25, up 5.07% from the previous close of Rs 1,081.45. The stock also touched a fresh 52-week high of Rs 1,142.65 during the session.
Why did Orchid Pharma Share Price make news today?
Ans. Orchid Pharma Share Price made news because it reached a fresh 52-week high and finished well above the previous close. The supplied data confirms the price event, but it does not identify a company-specific catalyst.
What was Orchid Pharma’s market capitalisation?
Ans. Orchid Pharma’s market capitalisation stood at Rs 5,923.25 crore in the supplied dataset. That places it above the sector median market cap of Rs 729.99 crore and below the sector average of Rs 14,244.27 crore.
How expensive is Orchid Pharma Share Price on earnings?
Ans. Orchid Pharma Share Price is trading at a P/E of 747.32, which is far above the sector median of 32.39 and the sector average of 45.36. That makes the earnings multiple unusually high versus the benchmark.
What do Orchid Pharma’s ROE and ROCE show?
Ans. Orchid Pharma’s ROE is 0.70% and ROCE is 1.11%. Both are below the same-industry medians of 11.78% and 13.65%, showing weaker returns than the supplied healthcare benchmark. ROE stands at 0.7%.
How does Orchid Pharma compare with peers?
Ans. Orchid Pharma’s market cap is close to IOLCP and FDC, but its P/E of 747.32 is far above the peer figures supplied. Its ROE and ROCE are also lower than the listed comparables.
